News

December 15, 2017
APRNIOIA Will participate 2018 Human Amyloid Imaging Conference
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.
December 15, 2017
APRNIOIA Will Participate 2018 AAT-AD/PD Focus Meeting
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.
December 15, 2017
​APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation
APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.
December 12, 2016
APRINOIA Will Present its 1st Clinical Trial Results at 2017 Human Amyloid Imaging Conference
APRINOIA will present the first-in-the-human clinical trial results for its Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2017.
December 12, 2016
2017 International Conference on Alzheimer’s Disease and Parkinson’s Disease
APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the 13th International Conference on Alzheimer's Disease and Parkinson's Disease (AD&PD) in Vienna in March 2017.
December 5, 2016
Hosts 2016 Taiwan Neuroscience Conference
APRINOIA is proud to host 2016 Taiwan Neuroscience Conference with Development Center for Biotechnology (DCB) and Academia Sinica on the 5th December 2016.
November 20, 2016
US FDA Approved APRINOIA Conduct Clinical Trial
APRINOIA has received written approval from the US FDA to conduct the first-in-the-human clinical trial in the US.